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Pharmaco-economic
assessment of the HMG-
CoA reductase inhibitors
A. J. Smart, l. Waiters
Objective. To perform a comparative pharmaco-economic
assessment of two HMG-CoA reductase inhibitors.
Design. A cost-effectiveness analysis was employed
using comparative'efficacy data from selected clinical
trials. A comprehensive international literature search
formed the basis for this selection. Criteria for inclusion of
clinical trial results in the analysis were set a priori.
Acquisition costs used were the recommended
reimbursement prices as at September 1994.
Ma/n outcome measures. Two outcome measures are
reported: (i) the comparative cost-effectiveness in lowering
blood lipid concentrations; and (ii) the comparative cost-
effectiveness of the medicines when used to achieve a
predetermined therapeutic goal.
Results. The average cost per 1% decrease in total
cholesterol is 21,9% higher on 10 mg pravastatin daily
than on 10 mg simvastatin daily. Similarly the average cost
per 1% decrease in low-density lipoprotein (LDL)
cholesterol is 23,1% higher on 10 mg pravastatin than on
10 mg simvastatin daily. This difference is consistent
throughout the dosage range. The use of incremental
doses of simvastatin monotherapy in order to reach a
predetermined therapeutic goal (LDL ,,:; 4,14 mmol/I) is
more cost-effective than an equivalent pravastatin dosage
regimen. Total treatment costs for simvastatin-treated
patients are 3,5% less than for pravastatin-treated
patients. More pa~ients on simvastatin are successfully
treated; the difference in overall treatment costs per
successfully treated patient is 27,9% in favour of
simvastatin. Sensitivity analysis shows these results to be
stable under extreme scenarios.
Conclusions. This analysis employed objective
comparative efficacy data obtained from peer-reviewed
sources to compare the economic and clinical outcomes
of simvastatin and pravastatin in the treatment of
hypercholesterolaemia. The acquisition cost of simvastatin
is 10,3 - 22,8% higher than an equivalent milligram dose of
pravastatin, depending on the dosage used. However,
because of the greater milligram potency of simvastatin, it
is a more cost-effective alternative. Simvastatin therefore
provides better value for money than pravastatin in
lowering lipid levels in clinical practice.
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Coronary heart disease (CHD) is one of the major causes of
morbidity and mortality in the Western world. Primary
hypercholesterolaemia is an established risk factor for CHD
and elevated plasma cholesterol levels have been shown to
impose a graded and continuous risk for CHD.' It has been
firmly established that a reduction of total and low-density
lipoprotein (LDL) cholesterol concentrations is accompanied
by a decrease in the incidence of CHD morbidity and
mortality. '-3
In the pharmacological treatment of primary
hypercholesterolaemia, the HMG-CoA reductase inhibitors
are emerging as the preferred pharmacological therapy! The
two agents in this class currently available in South Africa
are simvastatin and pravastatin.
As a result of variations in efficacy and costs among the
lipid-lowering agents, therapeutic decision-making regarding
the use of these agents is complex.5 Pharmaco-economic
analysis can assist with the rational selection of th~rapeutic
agents and help to ensure that each health care rand is
spent in the most cost-effective manner. <
This paper reports on the comparative cost-effectiveness
of simvastatin and pravastatin. Two analyses are presented:
(i) the cost-effectiveness of each drug in lowering blood lipid
concentrations; and (ii) the cost-effectiveness of each drug
when used to achieve a predetermined therapeutic goal.
Method
In order to conduct a reliable cost-effectiveness analysis,
accurate data on the acquisition costs and comparative
efficacy of the drugs across their accepted dosage range
are required.
Data on the acquisition costs of simvastatin and
pravastatin were obtained from the South African
Pharmaceutical Ethical Price List of September 1994. Retail
prices were used in all calculations and the cost .of each unit
dose strength was utilised, Le. if a patient were taking a
10 mg dose, it was assumed that one 10 mg tablet was
taken and not half a 20 mg tablet Likewise if a patient were
taking a 20 mg dose it was assumed that one 20 mg tablet
was taken and not two 10 mg tablets. This is noteworthy as
the cost of the 20 mg tablet is not twice that of the 10 mg
tablet.
In order to obtain unbiased comparative efficacy data on
the two drugs, an extensive search of the Medline database
from 1988 to 1993 was conducted. This search was
supplemented with data ,from the Micromedix database and
a review of standard reference texts.
Studies identified from the literature search were screened
to ensure that: (i) the patients were on a lipid-lowering diet
prior to initiation of drug therapy; (ii) results were reported in
a dose-specific way; and (iii) efficacy was measured at least
4 weeks after initiation of therapy or change of dose.
From the studies that met these requirements. those
which were randomised and compared the two drugs within
the same study were selected.
Only the results of the randomised comparative studies
were used in the cost-effectiveness analysis. The mean
decrease in total and LDL cholesterol produced by each
dose of the drugs used in these studies was weighted by
the number of patients studied, and the weighted mean was
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used in the calculations. The comparative cost-effectiveness
of the drugs was calculated by dividing the cost of 1
month's supply of the drug by the average decrease in lipid
levels produced by that drug.
In order to assess the comparative cost-effectiveness of
the two drugs in achieving a predetermined therapeutic
goal, the studies were screened to identify those which
reported on treatment regimens after stepwise dosage
increments and accepted treatment target levels. The results
of these studies were costed out to account for the cost of
the drugs, doctor visits and Iipograms. The costing assumed
that all patients would require an initial consultation and a
follow-up consultation 6 weeks thereafter. It was also
assumed that a lipogram would be required at both these
visits, and that a patient not attaining target cholesterol
levels would require a further consultation and lipogram until
the target was reached, Whereafter annual monitoring would
be required. The total treatment costs were then divided by
the proportion of successfully treated patients to calculate
the cost per successfully treated patient.
A sensitivity analysis of the results was performed using




The comparative cost-effectiveness of equivalent milligram
doses of the two drugs are shown in Table I. The results are
presented as the comparative cost of lowering total and LDL
cholesterol by 1 percentage point. The observed difference
was consistent throughout the dosage range of the drugs.
Total treatment costs in clinical
practice
The literature search identified one large double-blind,
multicentre study< of 550 patients which best r~flects the
appropriate use of these drugs in clinical practice. This study
employed dose titration, followed interoational guidelines on
treatment endpoints, studied men and women aged 18 - 71
years and had reasonable entry criteria, including a LDL
cholesterol requirement greater than 4,14 mmol/l.
The results of this study were applied to calculate the
mean annual costs of treating a patient with incremental
doses of simvastatin or pravastatin. These data are shown in
Table 11.
Table 11. Mean annual costs of treating a patient with incremental
doses of simvastatin or pravastatin monotherapy to reach a
predetermined therapeutic goal (LDL "4,14 mmol/l)'
Resource Simvastatin Pravastatin
Cost per successfully treated patient
The cost per successfully treated patient is shown in
Table Ill. These data reflect the mean annual treatment costs
of lowering a given patient's LDL cholesterol to a specified
level.
"Retail price: Blue Book, September 1994.
tRAMS taJill1994 (TC, LDL, HDL, TRIG).
;RAMS tariff 1994 (general practitioner consultation).
Comparative costs
The acquisition costs of simvastatin are higher than the
costs of an equivalent dose of pravastatin. A daily 10 mg
dose of simvastatin costs 22,8% more, and a daily 20 mg
dose 10,3% more than the same dose of pravastatin.
Comparative efficacy
Twenty-four clinical studies that met the criteria for inclusion
in the study were identified."6-28 The weighted mean
reduction in total and LDL cholesterol obtained from the
results of the comparative studies on the 10 mg and 20 mg













Table I. Comparative costs, efficacy and cost-effectiveness of
simvastatin versus pravastatin (10 mg and 20 mg daily) Table Ill. Annual treatment costs and· cost per successfully

































A: Average overall treatment
costs per year R5699,13
B: Successfully treated patients
(reached an LDL < 4,14 mmoVI) 84%
C: Average cost per successfully






" Percentage difference between the drugs.
















"Indicates the pecentage difference between the two drugs.
LDL = low-density lipoprotein.
Discussion
The choice of appropriate and affordable pharmacotherapy
inevitably involves the comparison of different drugs within a
class.
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It is essential to compare not only the cost of the drug,
but also the clinical effects produced by that drug. Cheaper
does not necessarily mean better value. This is clearly
illustrated in this analysis of the HMG-CoA reductase
inhibitors.
Cost containment ve'rsus cost-
effectiveness
The retail price of simvastatin is 10,3 - 22,8% higher than an
equivalent milligram dose of pravastatin. However, due to
the greater effectiveness of simvastatin, the cost per 1%
decrease in cholesterol levels produced by simvastatin is
less than for pravastatin.
The average cost of lowering a patient's total and LDL
cholesterol by 1%, respectively, is 21,9% and 23,1% higher
on 10 mg pravastatin daily than it would be on the same
dose of simvastatin. Simvastatin therefore provides better
value for money in lowering cholesterol levels.
Cost-containment exercises tend to consider only the cost
of a drug and ignore cost-effectiveness or value for money.
Such exercises only lead to inefficiencies and greater overall
long-tenm costs.
Drug costs versus total treatment
costs
The actual cost of a drug should always be viewed in the
context of its effect on the total costs of treating a patient.
In this analysis, the more expensive drug (simvastatin)
resulted in 3,5% lower overall treatment costs per patient.
The lower overall treatment costs with simvastatin were a
result of its greater potency. The greater potency resulted in
patients requiring a lower average dose to produce the
intended effect which in turn lowered overall drug costs. The
greater potency of simvastatin also resulted in more patients
reaching their target cholesterol levels sooner, which in turn
resulted in lower overall consultation and lipogram costs.
Not only were the overall treatment costs lower on
simvastatin, but more patients were successfully treated
with this drug. Eighty-four per cent of patients on
simvastatin achieved the target of a LDL cholesterol level
below 4,14 mmol/l compared with 68% of pravastatin-
treated patients. The difference in overall treatment costs
per successfully treated patient was 27,9% in favour of
simvastatin.
These data clearly show that basing choice of drug on
price alone may not only result in higher overall treatment
costs, but can also result in poorer clinical outcomes.
Objectivity
Objectivity is essential to any pharmaco-economic
assessment. The results depend firmly on the availability of
unbiased data on the efficacy of the drugs being compared.
An extensive literature search of international databases was
therefore perfonmed to ensure the objectivity of the efficacy
data. Studies identified from the literature search were only
used in the analysis if they met pre-defined criteria for
design and protocol requirements.
This analysis used the lowest available input costs for
non-drug expenditure. This was done to underestimate any
potential differences between the drugs.
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The costs of screening for and treating adverse events
caused by the drugs and potential differences in patient
compliance on these drugs were not included in this
assessment as there is no convincing evidence to show that
the drugs differ significantly in these respects. 9• 29 Perceived
differences in the safety profiles of the two drugs are not
based on consistent scientific evidence.
A sensitivity analysis was also performed to assess the
stability of the results objectively.
Sensit!vity analysis
A sensitivity (or 'what if') analysis was performed on the
results, using the outer limits of efficacy data obtained from
the non-comparative studies identified. The monthly cost
range per percentage decrease in total cholesterol produced
by simvastatin 10 mg was R9,61 - R10,53 and by.,
simvastatin 20 mg, R11 ,88 - R12,79. The corresponding
costs for pravastatin 10 mg and 20 mg were R10,59 {
R13,84 and R12,56 - R17,74, respectively. These data show
the results to be relatively stable under an extreme scenario.
As part of the sensitivity analysis, the costs of adding
varying doses of cholestyramine to the treatment regimen of
patients who have not reached their target cholesterol level
were calculated. When it was assumed that all patients had
reached the target cholesterol level on cholestyramine, the
difference in overall treatment costs between drugs was
18,2 - 26,3% in favour of simvastatin, depending on the
cholestyramine doses used.
Relevance of this analysis
Drummond et al. 3O have shown that the results obtained from
cost-effectiveness analyses of lipid-lowering drugs depend
on the unit of outcome measured. Different units of outcome
have been proposed3O and include CHD events avoided,
CHD-free life years gained, life years gained and quality-
adjusted life years gained. These clinical coronary outcomes
have not been taken into account in this analysis as the
measurement of these outcomes requires reliable data on
CHD treatment costs, non-CHD mortality rates, recjuction in
CHD risk and/or quality-of-Iife data, which are not yet readily
available in South Africa. We feel that the unit presented in
this analysis (cost per percentage reduction in lipid level) is
relevant for the practising clinician who is seeking to reduce
cholesterol levels. Our analysis is based on objective,
verifiable data and qoes not require sophisticated modelling
or the use of ambitious assumptions.
The second analysis presented in this paper is of total
treatment costs with incremental dose therapy. This analysis
was based on the results of one large clinical study and
assumes that treatment is initiated to achieve
predetenmined, accepted therapeutic goals. This approach
is consistent with international guidelines oh the treatment of
hypercholesterolaemia. The results cannot account for
individual differences that may occur in clinical practice.
Furthermore the results can only be extrapolated to patients
with baseline cholesterol profiles similar to those studied.
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Conclusion
This analysis highlights the importance of pharmaco-
economic analyses in promoting appropriate decision-
making, eliminating inefficiencies and lowering overall health
care costs.
Simvastatin, although currently more expensive than
pravastatin, is more cost-effective in lowering lipid levels.
This study was supported in part by a grant from Logos
Pharmaceuticals (pty) Ltd. The authors were independently
responsible for the study design, interpretation of the data and
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Dokter en digter
Fantasia I: Die aand
Gee my die glorie van sonsondergang
As wolke dik !E§ aan die Westerkim
Dis goud en purper, pers en diepste rooi
Wat op die hemeltrans word uitgestrooi
Totdat die pragkleur breek, en stilletjies
Versag in teerste blou en karmosyn
Gee my die aandblom met haar heuning-geur
Om langsaam in die duisternis te vaar
En in die wereld van my drome woon
Die vonkelende lig verdof
Omsluit deur newels wat sy glans verlei
o bleek verboeding van my groot verlange
AI swaarder word die voorbestemde vrag
Waarmee ek struikel deur die duisternis
en met loodswaar voete kruip die nag verby
Kan mens die Iig vang na die daglik sterwe?
Met skemering, toe die vinke by die vlei
Die lug deurweef het met hul helder geel
Die weemoed wat met skemer daal
Die lag wat deurbreek deur die traan
Verlig die duister om ons heen.
Die see sy sagte aandgebed laat hoor
Kyk hoe die alwee kand'laars teen die hang
Aan brand gesteek word deur die Westerson!
Met mantels van skarlaken, goud-omsoom
Staan wolke in die weste saamgeskaar:
In die draaikolk van die duisternis
Wat nou die klere uit die weste suig
En soos 'n dief sluip die nag die bulte oor
Om hierdie laaste dromerige ligte
Met sterk swart vingers te vermoor.
Die wonder van die aandblom het eindelik gebeur
In laagtes wat soos wierookblomme oorloop van sy geur
En dit in heuningvlae oor die ganna sprei
'Ekuphumleni'
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